2023 Was a troublesome year for the biopharma business, with a number of companies downsizing and restructuring their workforces to stay afloat. There are actually signs of Restoration, as mergers and acquisitions picked up over the pharmaceutical and daily life sciences sector inside the latter A part of 2023 and https://sites.google.com/view/bio-sites/blog